1997年5月，先于其他跨国生物制药公司，诺和诺德在中国建立了第一家生物技术研究发展中心。

2004年，研发中心从北京亦庄迁至中关村生命科学园。

2010年，诺和诺德宣布加大对研发中心的投资，并计划于5年内投资总额超过1亿美元，用于扩建研发中心。

2012年，扩建后的研发中心在北京中关村生命科学园落成，设施占地面积约16000多平米，员工逾200人。为跨国制药企业在华设立的大型研发中心之一。

研发中心拥有先进的研发设备和世界一流的科研环境，聘用了国内及海外优秀的创新型人才。目前设有四个研发板块：新药研发生物部，新药研发技术部，微生物蛋白质工程研究部及中试中国研究部。研发领域覆盖糖尿病，肥胖症，生长激素缺乏症及血友病等疾病。

研发中心管理团队及项目负责人均为国内及欧美从事过多年科研工作的研发人员及学术专家。研发中心专注于研发治疗性蛋白药物，目前研发重点包括生物技术的发展、蛋白质工程技术在生物制药中的应用、药物靶标的发现与筛选、抗体新技术、药理学、细胞生物学及工艺过程开发等。 

2007年，诺和诺德与中国科学院合作，设立了“诺和诺德 – 中科院科学研究经费”。该经费用于资助中国科学院及研发中心在糖尿病，生物制药及蛋白科学领域的科研项目与互动，资助范围包括科研项目，科学研讨会，博士及博后奖学金，科研互访和交流等。该经费还支持过“诺和诺德–中科院蛋白质研究教授奖”, 以支持中科院冉冉升起的科研新星。该经费总注资580万美元。

2009年，诺和诺德与中科院上海生命科学研究院合作，设立了“诺和诺德-上海生命科学研究院糖尿病前期转化型研究中心”。

2010年，诺和诺德公司注资100万美元，与中国医学科学院合作，设立了““诺和诺德-协和糖尿病研究英才基金”，以吸引和支持优秀的科学家及临床人员从事糖尿病研究。

2012年，诺和诺德公司注资100万美元，与上海转化医学中心合作，设立了“诺和诺德中国血友病研究基金”，致力于血友病的基础研究及治疗探索。

点击Scientific cooperation了解更多。

In 1997, Novo Nordisk established the first biotechnology R&D center among multinational pharmaceutical companies in China.

In 2004, Novo Nordisk R&D China relocated from Yizhuang to bigger facilities at Beijing Zhongguancun Life Science Park.

In 2010, Novo Nordisk announced that in next 5 years, it would invest additionally 100 million USD to expand its R&D activities in China.

In 2012, NNRCC facility in Beijing Zhongguancun Life Science Park was inaugurated.

Currently NNRCC covers more than 16,000 square meters and employs more than 200 people. It is one of the biggest research centers set up by global pharmaceutical companies in China.

NNRCC has advanced R&D facilities and world class research environment. It employs innovative talents from China and abroad. Currently, NNRCC has four research functions: Discovery Biology, Discovery Technology, E.coli Research, and CMC Mini-pilot. The research areas cover diabetes, obesity, growth hormone deficiency and haemophilia. 

NNRCC's research management teams and project leaders are scientists and experts with extensive research experiences gained in US, Europe, or China. NNRCC’s main research area is therapeutic protein discovery and development, currently with focus on technology development and application for protein engineering, drug target and drug hit identification and validation, new antibody technology, pharmacology, cell biology, protein production and process development. As an integral part of Novo Nordisk Global R&D, NNRCC takes part in various drug discovery projects, and conducts advanced research with the cutting edge biotechnology tools and methodologies.

In 2007, Novo Nordisk  and Chinese Academy of Sciences (CAS) established the Novo Nordisk - Chinese Academy of Sciences Research Fund. The Fund supports projects of interest to both CAS and Novo Nordisk in the fields of diabetes, biopharmaceuticals and protein sciences The projects include research projects, workshops, PhD fellowships and PostDoc fellowships, and exchange visits. The Fund has also supported CAS-NN Great Wall Professorships in Protein Sciences to build relations to rising stars at CAS. In total, Novo Nordisk has donated 5.8 million USD to the Fund.

In 2009, Novo Nordisk  and Shanghai Institutes for Biological Sciences (SIBS), CAS, established and jointly funded SIBS-NN Translational Research Center for PreDiabetes in Shanghai.

In 2010, Novo Nordisk  donated one million USD to establish "NN-UNION Diabetes Research Talent Fund” in cooperation with Chinese Academy of Medical Sciences to attract and support outstanding scientists and clinicians engaged in diabetes research.

In 2012, Novo Nordisk  donated one million USD to establish "Novo Nordisk Haemophilia Research Fund” for basic research and exploratory treatment of hemophilia in cooperation with Shanghai Center for Translational Medicine. 

Click Scientific cooperation to read more.